Volume 43, Issue 11 pp. 2583-2589
Basic Science

Oral antibiotics as a novel therapy for arthritis: Evidence for a beneficial effect of intestinal Escherichia coli

Edward E. S. Nieuwenhuis

Edward E. S. Nieuwenhuis

Wilhelmina Children's Hospital, Utrecht, The Netherlands

Search for more papers by this author
Maarten R. Visser

Maarten R. Visser

University Medical Center Utrecht, Utrecht, The Netherlands

Search for more papers by this author
Annemieke Kavelaars

Annemieke Kavelaars

Wilhelmina Children's Hospital, Utrecht, The Netherlands

Search for more papers by this author
Pieter M. Cobelens

Pieter M. Cobelens

Wilhelmina Children's Hospital, Utrecht, The Netherlands

Search for more papers by this author
Andre Fleer

Andre Fleer

University Medical Center Utrecht, Utrecht, The Netherlands

Search for more papers by this author
Wil Harmsen

Wil Harmsen

University Medical Center Utrecht, Utrecht, The Netherlands

Search for more papers by this author
Jan Verhoef

Jan Verhoef

University Medical Center Utrecht, Utrecht, The Netherlands

Search for more papers by this author
Louis M. A. Akkermans

Louis M. A. Akkermans

University Medical Center Utrecht, Utrecht, The Netherlands

Search for more papers by this author
Cobi J. Heijnen

Corresponding Author

Cobi J. Heijnen

Wilhelmina Children's Hospital, Utrecht, The Netherlands

Department of Pediatric Immunology, Room KC 03.068.0, Wilhelmina Children's Hospital of the University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The NetherlandsSearch for more papers by this author

Abstract

Objective

The intestinal flora is thought to play an important role in regulation of immune responses. We investigated the effects of changing the intestinal flora on the course of adjuvant-induced arthritis (AIA) and on experimental autoimmune encephalomyelitis (EAE) by the use of oral antibiotics.

Methods

Oral treatment with either vancomycin or vancomycin, tobramycin, and colistin was started after AIA and EAE induction. Clinical symptoms of AIA and EAE were monitored, and microbial analysis of ileal samples was performed.

Results

Oral vancomycin treatment after disease induction significantly decreased clinical symptoms of AIA. Simultaneously, increased concentrations of Escherichia coli were detected in the distal ileum of vancomycin-treated rats. Ileal concentrations of E coli were inversely related to disease scores in rats with AIA. Coadministration of colistin/tobramycin to prevent the increase in E coli abrogated the beneficial effect of vancomycin on AIA. Vancomycin treatment also reduced the clinical symptoms of EAE.

Conclusion

We propose oral vancomycin as a novel therapeutic strategy in autoimmune diseases.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.

click me